Nociscan is the first augmented intelligence platform to measure pain biomarkers in the lumbar spine.

Product release 2.7 enhances ease of use for physicians and builds additional scalability and security into the platform.

BROOMFIELD, CO - (NewMediaWire) - June 18, 2024 - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain (cLBP), announced today the product release of Nociscan 2.7 which includes ease-of-use enhancements for referring physicians while building additional scalability and security into the platform.

“The 2.7 release streamlines the delivery and accessibility of Nocigram reports for referring physicians through Aclarion’s web portal and our imaging center customers through their PACS system,” stated Brent Ness, CEO of Aclarion.  “Our engineering team has dramatically expanded scalability of the platform in important ways that efficiently enable greater throughput as Aclarion continues to grow with existing and new customers alike. Additionally, 2.7 leverages important security features of our technology partners which help customers ensure patient data is protected, a critically important aspect of healthcare today.”

“Aclarion’s mission is to change the paradigm in spinal diagnostics and for Nociscan to become the standard decision support tool used in the diagnosis and treatment of chronic low back pain,” said Ryan Bond, Chief Strategy Officer of Aclarion. “These product enhancements serve as building blocks for future product releases that will increasingly incorporate best practice machine learning techniques as we complete the transition of Nociscan from an augmented intelligence platform to an artificial intelligence platform expected to deliver additional performance enhancements, reinforcing our focus on customers and our mission.”

The advancement of augmented intelligence decision support solutions like Nociscan is rapidly improving the lives of millions of patients.  Aclarion is honored to be leading the industry in addressing a global healthcare problem that impacts approximately 266 million people who suffer from degenerative spine disease and low back pain.

Recently, Aclarion announced Nociscan will play a key role in the groundbreaking LIFEHAB Trial. For more information, please visit: https://aclarion.com/news/ 

About Aclarion, Inc.

Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies.  For more information, please visit www.aclarion.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contacts:

Kirin M. Smith

PCG Advisory, Inc.

646.823.8656

ksmith@pcgadvisory.com

Media Contacts:

Jodi Lamberti

SPRIG Consulting

612.812.7477

jodi@sprigconsulting.com